Lukas Flatz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lukas Flatz has a total of 537 co-authors. Here are the top co-authors by number of shared publications:
Marie-Therese Abdou
Department of Dermatology, Institute of Immunobiology, St. Gallen, Switzerland
10 shared publicationsFiamma Berner
Institute of Immunobiology
8 shared publicationsDavid Bomze
Institute of Immunobiology, Kantonsspital St. Gallen, 9007 St. Gallen, Switzerland
7 shared publications- Omar Hasan Ali
Department of Life Sciences, University of British Columbia, Vancouver, Canada
7 shared publications Antonio Cozzio
Department of Dermatology, and
6 shared publications- Ann-Kristin Jochum
Institute of Immunobiology, Kantonsspital St. Gallen, St. Gallen, Switzerland
5 shared publications
Latest Publications
- Open Access
- 5 November 2026
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 75 (11) , 271
Tinostamustine–nivolumab therapy is associated with antigen-specific cellular and humoral immune responses in heavily pre-treated patients with advanced melanoma
ENIgMA is a phase IB trial (NCT03903458; SNCTP000003243) evaluating the safety and preliminary activity of the first-in-class alkylating deacetylase inhibitor tinostamustine in combination with nivolumab (3 mg/kg) in patients with predominantly immune checkpoint inhibitor (ICI)-resistant, advanced melanoma. We conducted this longitudinal immune monitoring study in 15 of the 17 enrolled patients to characterize systemic immunologic changes associated with an immunomodulatory dose of tinostamustine. We have previously demonstrated that combination of tinostamustine with nivolumab was able to induce disease stabilization in 54% and confirmed partial responses in 23% of evaluable patients. Peripheral blood samples collected longitudinally during treatment were analysed by flow cytometry, serum antigen-specific IgG enzyme-linked immunosorbent assay (ELISA), and intracellular cytokine staining following ex vivo peptide stimulation. Longitudinal flow cytometric analyses demonstrated dynamic changes in peripheral immune subsets, including T cells, natural killer (NK) cells and monocytes, suggesting ongoing immune engagement during tinostamustine–nivolumab therapy. In progressors, elevated baseline lactate dehydrogenase (LDH) levels significantly and inversely correlated with circulating T cell frequencies, indicating distinct immune profiles associated with poor clinical outcome. Antigen-specific adaptive immune responses were detectable despite extensive prior treatment and high tumour burden. CD4+ T cell responses, particularly TNFα-associated responses directed against melanoma-associated antigens, represented the dominant cellular immune activation pattern. Additionally, treatment related increases in melanoma-associated antigen-specific IgG responses were also observed in several patients. Collectively, these findings demonstrate that immunomodulatory doses of tinostamustine in combination with nivolumab are linked with preserved adaptive immune competence and detectable cellular and humoral immune activation in heavily pre-treated patients with advanced melanoma.
- 5 November 2026
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 75 (11) , 271
Open AccessTinostamustine–nivolumab therapy is associated with antigen-specific cellular and humoral immune responses in heavily pre-treated patients with advanced melanoma
ENIgMA is a phase IB trial (NCT03903458; SNCTP000003243) evaluating the safety and preliminary activity of the first-in-class alkylating deacetylase inhibitor tinostamustine in combination with nivolumab (3 mg/kg) in patients with predominantly immune checkpoint inhibitor (ICI)-resistant, advanced melanoma. We conducted this longitudinal immune monitoring study in 15 of the 17 enrolled patients to characterize systemic immunologic changes associated with an immunomodulatory dose of tinostamustine. We have previously demonstrated that combination of tinostamustine with nivolumab was able to induce disease stabilization in 54% and confirmed partial responses in 23% of evaluable patients. Peripheral blood samples collected longitudinally during treatment were analysed by flow cytometry, serum antigen-specific IgG enzyme-linked immunosorbent assay (ELISA), and intracellular cytokine staining following ex vivo peptide stimulation. Longitudinal flow cytometric analyses demonstrated dynamic changes in peripheral immune subsets, including T cells, natural killer (NK) cells and monocytes, suggesting ongoing immune engagement during tinostamustine–nivolumab therapy. In progressors, elevated baseline lactate dehydrogenase (LDH) levels significantly and inversely correlated with circulating T cell frequencies, indicating distinct immune profiles associated with poor clinical outcome. Antigen-specific adaptive immune responses were detectable despite extensive prior treatment and high tumour burden. CD4+ T cell responses, particularly TNFα-associated responses directed against melanoma-associated antigens, represented the dominant cellular immune activation pattern. Additionally, treatment related increases in melanoma-associated antigen-specific IgG responses were also observed in several patients. Collectively, these findings demonstrate that immunomodulatory doses of tinostamustine in combination with nivolumab are linked with preserved adaptive immune competence and detectable cellular and humoral immune activation in heavily pre-treated patients with advanced melanoma.
- 1 October 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (28) , 2662-2669
Neoadjuvant Intralesional Daromun (L19IL2/L19TNF) in Resectable Locally Advanced Melanoma: An Update on the Efficacy and Safety Results of the PIVOTAL Phase III Trial
Daromun (L19IL2/L19TNF) was investigated as a neoadjuvant, intralesional therapy for patients with fully resectable stage III melanoma in the phase III PIVOTAL trial (ClinicalTrials.gov identifier: NCT02938299 ). The trial enrolled 256 patients in the European Union and met its primary end point, demonstrating a statistically significant improvement in recurrence-free survival (RFS; hazard ratio, 0.59; P = .005) for daromun followed by surgery versus up-front surgery, at a median follow-up (FU) of 21 months from random assignment. PIVOTAL included two clinically distinct subgroups, namely, patients with de novo diagnosed metastatic disease (n = 34; 13%) and patients with recurrence(s) after surgery with or without radiotherapy and/or adjuvant systemic therapies (n = 222; 87%). Here, we present an updated analysis of the primary and secondary end points, including safety data, at a median FU of 36.8 months from random assignment (database cutoff: November 28, 2025), alongside new sensitivity analyses of event-free survival (EFS). The updated analysis confirms the clinically and statistically meaningful improvements in RFS and distant metastasis-free survival recorded in the neoadjuvant daromun versus control arm. The EFS post hoc analysis, conducted in both the overall population and the recurrent patient subgroups (with or without prior systemic therapies), provides consistency and robustness to the benefit of neoadjuvant daromun observed for the primary efficacy end point. No new safety signals of concern were recorded.
- 1 October 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (28) , 2662-2669
Neoadjuvant Intralesional Daromun (L19IL2/L19TNF) in Resectable Locally Advanced Melanoma: An Update on the Efficacy and Safety Results of the PIVOTAL Phase III Trial
Daromun (L19IL2/L19TNF) was investigated as a neoadjuvant, intralesional therapy for patients with fully resectable stage III melanoma in the phase III PIVOTAL trial (ClinicalTrials.gov identifier: NCT02938299 ). The trial enrolled 256 patients in the European Union and met its primary end point, demonstrating a statistically significant improvement in recurrence-free survival (RFS; hazard ratio, 0.59; P = .005) for daromun followed by surgery versus up-front surgery, at a median follow-up (FU) of 21 months from random assignment. PIVOTAL included two clinically distinct subgroups, namely, patients with de novo diagnosed metastatic disease (n = 34; 13%) and patients with recurrence(s) after surgery with or without radiotherapy and/or adjuvant systemic therapies (n = 222; 87%). Here, we present an updated analysis of the primary and secondary end points, including safety data, at a median FU of 36.8 months from random assignment (database cutoff: November 28, 2025), alongside new sensitivity analyses of event-free survival (EFS). The updated analysis confirms the clinically and statistically meaningful improvements in RFS and distant metastasis-free survival recorded in the neoadjuvant daromun versus control arm. The EFS post hoc analysis, conducted in both the overall population and the recurrent patient subgroups (with or without prior systemic therapies), provides consistency and robustness to the benefit of neoadjuvant daromun observed for the primary efficacy end point. No new safety signals of concern were recorded.
- 3 September 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 393 (6815) , 1036-1044
Tumor-derived antioxidants suppress immunity by depriving T cells of reactive oxygen species
Reactive oxygen species (ROS) promote genomic instability and fuel oncogenic signaling in cancer, but antioxidant therapies have so far failed to improve, or worsen, cancer outcomes. Emerging data suggest that T cells depend on ROS for signal transduction. In this study, we show that tumors exploit this dependency, releasing antioxidant enzymes into the tumor environment to suppress T cell–mediated antitumor immunity. The interstitial fluid of tumors possesses potent antioxidant activity, associated with enrichment of the antioxidant enzyme peroxiredoxin 1 (PRDX1). Extracellular PRDX1 deprives T cells of ROS, preventing oxidative inactivation of phosphatases required for T cell receptor–driven kinase signaling and effector function. Prdx1 is up-regulated upon cancer immunoediting, and loss of PRDX1 within tumors enhances antitumor immunity and immunotherapy responses. These findings define a redox-dependent mechanism of tumor immunosuppression that is potentially amenable to therapeutic intervention.
- 3 September 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 393 (6815) , 1036-1044
Tumor-derived antioxidants suppress immunity by depriving T cells of reactive oxygen species
Reactive oxygen species (ROS) promote genomic instability and fuel oncogenic signaling in cancer, but antioxidant therapies have so far failed to improve, or worsen, cancer outcomes. Emerging data suggest that T cells depend on ROS for signal transduction. In this study, we show that tumors exploit this dependency, releasing antioxidant enzymes into the tumor environment to suppress T cell–mediated antitumor immunity. The interstitial fluid of tumors possesses potent antioxidant activity, associated with enrichment of the antioxidant enzyme peroxiredoxin 1 (PRDX1). Extracellular PRDX1 deprives T cells of ROS, preventing oxidative inactivation of phosphatases required for T cell receptor–driven kinase signaling and effector function. Prdx1 is up-regulated upon cancer immunoediting, and loss of PRDX1 within tumors enhances antitumor immunity and immunotherapy responses. These findings define a redox-dependent mechanism of tumor immunosuppression that is potentially amenable to therapeutic intervention.
- Open Access
High immune receptor clonality in melanoma-draining lymph nodes associates with immune dysfunction and poor survival
Tumor-draining lymph nodes (tdLNs) are critical hubs of anti-tumor immunity but are also vulnerable to tumor-mediated immunosuppression. We analyzed T cell and B cell receptor (TCR/BCR) repertoires and transcriptomes from sentinel and non-sentinel lymph nodes of patients with melanoma from a historical pre–immune checkpoint inhibitor cohort (1994-2002) and an independent contemporary validation cohort (2022-2024). Melanoma-positive lymph nodes exhibited increased immune receptor clonality compared with tumor-free nodes. While average clonality showed no consistent association with outcome, the presence of extreme high-clonality outliers in individual lymph nodes was strongly associated with poor melanoma-specific survival. These outliers were characterized by a loss of lymphocyte-related genes and activation markers, an enrichment of melanocytic transcripts, and the suppression of immune signaling pathways, consistent with local immune dysfunction. Increased clonality was confined to lymph nodes and not observed in the peripheral blood. T cell responses to melanocyte differentiation antigens were infre-quently shared between lymph nodes and peripheral blood, highlighting immune compartmentalization.
Open AccessHigh immune receptor clonality in melanoma-draining lymph nodes associates with immune dysfunction and poor survival
Tumor-draining lymph nodes (tdLNs) are critical hubs of anti-tumor immunity but are also vulnerable to tumor-mediated immunosuppression. We analyzed T cell and B cell receptor (TCR/BCR) repertoires and transcriptomes from sentinel and non-sentinel lymph nodes of patients with melanoma from a historical pre–immune checkpoint inhibitor cohort (1994-2002) and an independent contemporary validation cohort (2022-2024). Melanoma-positive lymph nodes exhibited increased immune receptor clonality compared with tumor-free nodes. While average clonality showed no consistent association with outcome, the presence of extreme high-clonality outliers in individual lymph nodes was strongly associated with poor melanoma-specific survival. These outliers were characterized by a loss of lymphocyte-related genes and activation markers, an enrichment of melanocytic transcripts, and the suppression of immune signaling pathways, consistent with local immune dysfunction. Increased clonality was confined to lymph nodes and not observed in the peripheral blood. T cell responses to melanocyte differentiation antigens were infre-quently shared between lymph nodes and peripheral blood, highlighting immune compartmentalization.
- 14 November 2025
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (6)
Genetic susceptibility in early‐onset melanoma: An observational Greek cohort study
- 14 November 2025
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (6)
Genetic susceptibility in early‐onset melanoma: An observational Greek cohort study
- Open Access
- 13 October 2025
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (3) , 377-386
Precision medicine in cutaneous melanoma—A comprehensive review
Precision medicine aims to tailor medical treatment to the individual characteristics of each patient, beginning with detailed diagnostic assessments. In cutaneous melanoma, precision medicine has made considerable progress, with some approaches already implemented in clinical practice and guidelines. For instance, testing for BRAF mutations to guide the use of targeted BRAF/MEK inhibitor therapy is an established standard of care. Even melanoma with rarer genetic alterations, such as NTRK fusions or KIT mutations, can increasingly be treated with specific targeted therapies. These advancements have translated into significant improvements in overall survival, especially in patients with metastatic disease. Other innovative approaches, such as gene expression profiling (GEP) and the use of circulating tumour DNA (ctDNA) for monitoring treatment response, are already available. However, they are not yet part of routine clinical care or broadly recommended in guidelines. Likewise, the use of tumour‐infiltrating lymphocytes (TIL) remains limited to specialized centres, and tailor‐made mRNA vaccines are still in the investigational phase but hold great promise for the future of melanoma therapy. This review provides an overview of current and emerging approaches in precision therapy and diagnostics for melanoma, encompassing key areas such as molecular and genomic profiling, advanced imaging techniques, biomarker‐based stratification and AI‐driven technologies.
- 13 October 2025
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (3) , 377-386
Open AccessPrecision medicine in cutaneous melanoma—A comprehensive review
Precision medicine aims to tailor medical treatment to the individual characteristics of each patient, beginning with detailed diagnostic assessments. In cutaneous melanoma, precision medicine has made considerable progress, with some approaches already implemented in clinical practice and guidelines. For instance, testing for BRAF mutations to guide the use of targeted BRAF/MEK inhibitor therapy is an established standard of care. Even melanoma with rarer genetic alterations, such as NTRK fusions or KIT mutations, can increasingly be treated with specific targeted therapies. These advancements have translated into significant improvements in overall survival, especially in patients with metastatic disease. Other innovative approaches, such as gene expression profiling (GEP) and the use of circulating tumour DNA (ctDNA) for monitoring treatment response, are already available. However, they are not yet part of routine clinical care or broadly recommended in guidelines. Likewise, the use of tumour‐infiltrating lymphocytes (TIL) remains limited to specialized centres, and tailor‐made mRNA vaccines are still in the investigational phase but hold great promise for the future of melanoma therapy. This review provides an overview of current and emerging approaches in precision therapy and diagnostics for melanoma, encompassing key areas such as molecular and genomic profiling, advanced imaging techniques, biomarker‐based stratification and AI‐driven technologies.
- Open Access
- 22 September 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (9) , e011590
HLA-A*01:01-B*08:01-C*07:01 is linked to early-onset immune checkpoint inhibitor-induced myositis and myocarditis
Background: Immune-related myotoxicity (irM), including irMyocarditis and irMyositis, is a severe complication of immune checkpoint inhibitors (ICIs). Markers to identify patients at risk are missing. In this retrospective multicenter cohort study, we aimed to determine whether specific human leukocyte antigen (HLA) variants are associated with irM. Methods: Twenty patients with irMyocarditis and/or irMyositis (median age (IQR), 67 (60–73) years; 7/20 female) and 60 cancer controls (CC) without immune-related adverse events (median age (IQR), 68 (62–74) years; 26/60 female) presenting to Charité - Universitätsmedizin Berlin, Germany, or Kantonsspital St. Gallen, Switzerland, between September 2017 and June 2024, were included. As a second control cohort, we used HLA data from a historic dataset of 5.1×10⁶ German healthy donors (G-HD). Allele frequencies (AF) of two-field HLA types were compared between patients with irM, CC, and G-HD using logistic regression and two-sided z-tests of odds ratios (OR). Results: Comparison of single HLA AF between patients with irM and G-HD revealed moderate associations for irM with B*07:02 (OR 2.29; 95% CI 1.12 to 4.69; p=0.023), B*40:01 (OR 2.75; 95% CI 1.08 to 7.02; p=0.035), C*03:04 (OR 2.46; 95% CI 1.09 to 5.56; p=0.031), DPB1*04:02 (OR 2.37; 95% CI 1.16 to 4.85; p=0.018), and DQB1*06:02 (OR 2.28; 95% CI 1.12 to 4.67; p=0.024). No statistically significant differences were observed between patients with irM and CC. By contrast, multi-allelic HLA analysis identified a strong association between HLA-A*01:01-B*08:01-C*07:01, a component of the 8.1 ancestral haplotype (8.1 AH), and early-onset irM (onset ≤3 months after ICI initiation, n=11), compared with G-HD (22.7% vs 7.6%; OR 3.59; 95% CI 1.33 to 9.74; p=0.012) and CC (22.7% vs 7.5%; OR 3.62; 95% CI 1.09 to 12.12; p=0.036). Intriguingly, early-onset irM was linked to higher troponin T levels compared with late-onset irM (p=0.005, Cohen’s r=0.63). Conclusions: Our results provide first evidence that early-onset irM with myocardial injury is linked to HLA-A*01:01-B*08:01-C*07:01, a component of the 8.1 AH, which is associated with various autoimmune diseases including idiopathic myopathies. If validated in larger cohorts, pretreatment screening for HLA-A*01:01-B*08:01-C*07:01 may help identify patients at risk of early-onset and severe irM.
- 22 September 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (9) , e011590
Open AccessHLA-A*01:01-B*08:01-C*07:01 is linked to early-onset immune checkpoint inhibitor-induced myositis and myocarditis
Background: Immune-related myotoxicity (irM), including irMyocarditis and irMyositis, is a severe complication of immune checkpoint inhibitors (ICIs). Markers to identify patients at risk are missing. In this retrospective multicenter cohort study, we aimed to determine whether specific human leukocyte antigen (HLA) variants are associated with irM. Methods: Twenty patients with irMyocarditis and/or irMyositis (median age (IQR), 67 (60–73) years; 7/20 female) and 60 cancer controls (CC) without immune-related adverse events (median age (IQR), 68 (62–74) years; 26/60 female) presenting to Charité - Universitätsmedizin Berlin, Germany, or Kantonsspital St. Gallen, Switzerland, between September 2017 and June 2024, were included. As a second control cohort, we used HLA data from a historic dataset of 5.1×10⁶ German healthy donors (G-HD). Allele frequencies (AF) of two-field HLA types were compared between patients with irM, CC, and G-HD using logistic regression and two-sided z-tests of odds ratios (OR). Results: Comparison of single HLA AF between patients with irM and G-HD revealed moderate associations for irM with B*07:02 (OR 2.29; 95% CI 1.12 to 4.69; p=0.023), B*40:01 (OR 2.75; 95% CI 1.08 to 7.02; p=0.035), C*03:04 (OR 2.46; 95% CI 1.09 to 5.56; p=0.031), DPB1*04:02 (OR 2.37; 95% CI 1.16 to 4.85; p=0.018), and DQB1*06:02 (OR 2.28; 95% CI 1.12 to 4.67; p=0.024). No statistically significant differences were observed between patients with irM and CC. By contrast, multi-allelic HLA analysis identified a strong association between HLA-A*01:01-B*08:01-C*07:01, a component of the 8.1 ancestral haplotype (8.1 AH), and early-onset irM (onset ≤3 months after ICI initiation, n=11), compared with G-HD (22.7% vs 7.6%; OR 3.59; 95% CI 1.33 to 9.74; p=0.012) and CC (22.7% vs 7.5%; OR 3.62; 95% CI 1.09 to 12.12; p=0.036). Intriguingly, early-onset irM was linked to higher troponin T levels compared with late-onset irM (p=0.005, Cohen’s r=0.63). Conclusions: Our results provide first evidence that early-onset irM with myocardial injury is linked to HLA-A*01:01-B*08:01-C*07:01, a component of the 8.1 AH, which is associated with various autoimmune diseases including idiopathic myopathies. If validated in larger cohorts, pretreatment screening for HLA-A*01:01-B*08:01-C*07:01 may help identify patients at risk of early-onset and severe irM.
- Open Access
- 10 May 2025
- Published by Elsevier in Cancer Letters
- Vol. 626, 217789
Association of CMV status with response to neoadjuvant chemoimmunotherapy in early triple-negative breast cancer
- 10 May 2025
- Published by Elsevier in Cancer Letters
- Vol. 626, 217789
Open AccessAssociation of CMV status with response to neoadjuvant chemoimmunotherapy in early triple-negative breast cancer
- Open Access
- 1 October 2024
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 210 (7) , 919-930
Autoimmunity Against Surfactant Protein B Is Associated with Pneumonitis During Checkpoint Blockade
Rationale: Immune checkpoint inhibitor (ICI)–related pneumonitis is a serious autoimmune event affecting as many as 20% of patients with non–small-cell lung cancer (NSCLC), yet the factors underpinning its development in some patients and not others are poorly understood. Objectives: To investigate the role of autoantibodies and autoreactive T cells against surfactant-related proteins in the development of pneumonitis. Methods: The study cohort consisted of patients with NSCLC who provided blood samples before and during ICI treatment. Serum was used for proteomics analyses and to detect autoantibodies present during pneumonitis. T-cell stimulation assays and single-cell RNA sequencing were performed to investigate the specificity and functionality of peripheral autoreactive T cells. The findings were confirmed in a validation cohort comprising patients with NSCLC and patients with melanoma. Measurements and Main Results: Across both cohorts, patients in whom pneumonitis developed had higher pretreatment levels of immunoglobulin G autoantibodies targeting surfactant protein (SP)-B. At the onset of pneumonitis, these patients also exhibited higher frequencies of CD4+ IFN-γ–positive SP-B–specific T cells and expanding T-cell clonotypes recognizing this protein, accompanied by a proinflammatory serum proteomic profile. Conclusions: Our data suggest that the cooccurrence of SP-B–specific immunoglobulin G autoantibodies and CD4+ T cells is associated with the development of pneumonitis during ICI therapy. Pretreatment levels of these antibodies may represent a potential biomarker for an increased risk of developing pneumonitis, and on-treatment levels may provide a diagnostic aid.
- 1 October 2024
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 210 (7) , 919-930
Open AccessAutoimmunity Against Surfactant Protein B Is Associated with Pneumonitis During Checkpoint Blockade
Rationale: Immune checkpoint inhibitor (ICI)–related pneumonitis is a serious autoimmune event affecting as many as 20% of patients with non–small-cell lung cancer (NSCLC), yet the factors underpinning its development in some patients and not others are poorly understood. Objectives: To investigate the role of autoantibodies and autoreactive T cells against surfactant-related proteins in the development of pneumonitis. Methods: The study cohort consisted of patients with NSCLC who provided blood samples before and during ICI treatment. Serum was used for proteomics analyses and to detect autoantibodies present during pneumonitis. T-cell stimulation assays and single-cell RNA sequencing were performed to investigate the specificity and functionality of peripheral autoreactive T cells. The findings were confirmed in a validation cohort comprising patients with NSCLC and patients with melanoma. Measurements and Main Results: Across both cohorts, patients in whom pneumonitis developed had higher pretreatment levels of immunoglobulin G autoantibodies targeting surfactant protein (SP)-B. At the onset of pneumonitis, these patients also exhibited higher frequencies of CD4+ IFN-γ–positive SP-B–specific T cells and expanding T-cell clonotypes recognizing this protein, accompanied by a proinflammatory serum proteomic profile. Conclusions: Our data suggest that the cooccurrence of SP-B–specific immunoglobulin G autoantibodies and CD4+ T cells is associated with the development of pneumonitis during ICI therapy. Pretreatment levels of these antibodies may represent a potential biomarker for an increased risk of developing pneumonitis, and on-treatment levels may provide a diagnostic aid.
- Open Access
- 19 September 2024
- Published by Springer Nature in Acta Neuropathologica Communications
- Vol. 12 (1) , 1-4
Correction: Neuropathological assessment of the olfactory bulb and tract in individuals with COVID-19
- 19 September 2024
- Published by Springer Nature in Acta Neuropathologica Communications
- Vol. 12 (1) , 1-4
Open AccessCorrection: Neuropathological assessment of the olfactory bulb and tract in individuals with COVID-19